Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Brain and pancreatic metastases: A clinico-pathological comparison of various facets of tumor heterogeneity in renal cell carcinoma - The BRAVE project

Date

09 Oct 2016

Session

Poster display

Presenters

Lisa Derosa

Citation

Annals of Oncology (2016) 27 (6): 266-295. 10.1093/annonc/mdw373

Authors

L. Derosa1, G. Le Teuff1, B. Chanez2, A. Guida1, F. Ruatta1, G. Gravis2, L. Albiges1, B. Escudier1

Author affiliations

  • 1 Medical Oncology, Gustave Roussy, 94805 - Villejuif/FR
  • 2 Medical Oncology, Institute Paoli Calmettes, 13009 - Marseille/FR
More

Resources

Abstract 2313

Background

Brain (BM) and pancreatic metastases (PM) from renal cell carcinoma (RCC) represent two faces of the same coin in terms of disease course: BM are associated with shorter overall survival (OS) compared with PM. The reasons for this difference have never been investigated. This is the objective of the BRAVE project.

Methods

From a few French centers, only RCC patients (pts) who underwent surgical resection or biopsy for BM or PM and with available histological tissue samples (TS) were enrolled. Medical records were retrospectively reviewed to determine patients' characteristics, prognostic factors and outcome. To identify factors which could differentiate BM and PM, we will perform: i) correlation between clinico-pathological characteristics and metastasis location (BM vs PM) ii) histopathological features description by TS review and iii) immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH) analyses in BM, PM and nephrectomy (Nx) TS.

Results

Out of 113 pts enrolled so far, most pts were male (67%), had clear-cell histology (98%) and underwent radical Nx (93%). Forty-seven pts (41%) underwent at least one metastasectomy (Mx) before BM or PM surgery. Sixty-two pts (55%) had BM and 51 (45%) had PM. Between BM and PM, there was no significant differences in baseline characteristics (sex, age at diagnosis of RCC, Nx, primary RCC (left vs right), histology, Fuhrmann, Mx) except for T stage: T3-T4 vs T1-T2 increased the risk of BM compared to PM (odds ratio: 4.17, 95%CI = [1.52-11.39], p 

Conclusions

BM and PM from RCC have a different natural history. Heterogeneity between biological markers expression inside PM and BM might explain these divergent outcomes.

Clinical trial identification

Not applicable

Legal entity responsible for the study

N/A

Funding

ESMO translational fellowship

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings